|
|
 |
|
Viewing report
|
|
|
|
2008 U.S. Diabetes Drug Delivery - Patient Perspective
Frost & Sullivan, May 2010, Pages: 68
This study encompasses feedback provided by U.S. diabetes patients on aspects of drug delivery and drug treatment for diabetes, enabling interested stakeholders to gain insight into current and future trends. Data was presented for the general objective point questions as well as analysis by disease subtype where applicable. Patient feedback about awareness, usage, and desired changes was obtained for Exubera and Byetta. For device driven delivery, autoinjector technology usage and willingness for adoption is assessed by patients, as well as other vital feedback on the role the device plays in the overall drug product. The corresponding physician deliverable is titled: 2008 U.S. Diabetes Drug Delivery - Physician Perspective.
Research Overview
This Frost & Sullivan research service titled 2008 U.S. Diabetes Drug Delivery - Patient Perspective presents feedback provided by the U.S. diabetes patients on aspects of drug delivery and drug treatment for diabetes. Data was presented for the general objective point questions as well as analysis by disease subtype where applicable.
Market Overview
The U.S. Diabetes Market - Issues and Trends in Drug Delivery
The U.S. diabetes market consists of a number of medications that give patients the flexibility to choose from multiple delivery methods. Diabetes drugs are delivered through injection, intravenous infusion, topical gel/cream, transdermal patch, vaginal, sublingual, pulmonary/inhaled, intranasal, implant, rectal, ocular, and oral. A survey was conducted among diabetes patients to understand their most preferred mode of delivery of medication. During the survey, respondents were also asked about general awareness of drug delivery types, availability and usage, frequency of usage, satisfaction and reason for satisfaction with method used, willingness and reasons for willingness to use, barriers for usage, and reasons for preferences.
“For Diabetes 1, while injection is currently the dominant (90 percent) mode of delivery, the availability and prescription of effective oral medication has the potential for higher patient acceptance compared to injection,” notes the analyst of this research service. “The majority of patients (52 percent) would prefer twice a day oral medication most likely because ‘easy to self administer’ is the top factor for drug delivery method.” For Diabetes 2, oral medication is almost completely dominant (99 percent), while injection is secondary (38 percent). Again, oral medication has the highest potential for patient acceptance compared to intravenous infusion. Patients are likely to prefer to take oral medication twice a day significantly more (68 percent versus. 20 percent) than a once a day injection. ‘Easy to self administer’ is again the dominant reason for preferring oral medication over injection. “Patients prefer injection and oral medication for type 1 and 2 diabetes as it is easy to administer,” notes the analyst. “Patients also prefer oral medications for its convenience and lack of pain discomfort, and injection medications because their doctor prefers it.”
The future of diabetes treatments is in the convenient drug delivery methods. Type-1 diabetic patients are most likely to prefer a twice-a-day oral dosing regimen, while type-2 diabetic patients are also expected to prefer a twice-a-day oral dosing regimen or a twice-a- day patch.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Diabetes
- Drug Delivery
Technologies
The following technologies are covered in this research:
- Autoinjectors
- Transdermal patch
- Oral drug delivery
- Intravenous infusion
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
U.S. Inflammatory Disease Drug Delivery - Patient Perspective
2008 U.S. Inflammatory Diseases Drug Delivery: Physician Perspective
2008 U.S. Drug Delivery: Neurological Disorders - Physician Perspective
U.S. Diabetes Drug Delivery - Physician Perspective
Transdermal Drug Delivery - Technologies, Markets, and Companies
2008 U.S. Chronic Pain Drug Delivery: Patient Perspective
U.S. Inflammatory Diseases Drug Delivery: Physician Perspective
2010 U.S. Type 2 Diabetes Patients’ Choice: Awareness, Usage, and Preferences of Insulin Injection Pens
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Pediatric Drug Delivery: Technology and Product Opportunities, 2nd Edition
|
|
|
|
